Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia

키워드

참고문헌 (57)

1. Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72314 cases from the Chinese center for disease control and prevention", JAMA, 323, pp.1239~1242 (2020)
2. Mi Young Ahn, "Four cases of coronavirus disease 2019 in the early stage of pandemic of South Korea: a single public hospital experience", The Korean Journal of Internal Medicine, 35(4), pp.788~792 (2020), 대한내과학회[DOI]
3. 이현우, "Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients", The Korean Journal of Internal Medicine, 36(1), pp.1~10 (2021), 대한내과학회[DOI]
4. Chen Q, "Mental health care for medical staff in China during the COVID-19 outbreak", Lancet Psychiatry, 7, pp.e15~e16 (2020)
5. Ferrario CM, "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2", Circulation, 111, pp.2605~2610 (2005)
6. Kreutz R, "Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury : implications for COVID-19", Cardiovasc Res, 116, pp.1688~1699 (2020)
7. Xu J, "The effect of prior ACEI", ARB treatment on COVID-19 susceptibility and outcome : a systematic review and meta-analysis, 2020, ~
8. Kim Jaiyong, "Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service", Journal of Korean Medical Science, 35(25), pp.1~12 (2020), 대한의학회[DOI]
9. Jung SY, "Association of reninangiotensin-aldosterone system inhibitors with coronavirus disease 2019(COVID-19)-related outcomes in Korea : a nationwide population-based cohort study", Clin Infect Dis, 71, pp.2121~2128 (2020)
10. Mortensen EM, "Populationbased study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumoniarelated outcomes", Clin Infect Dis, 55, pp.1466~1473 (2012)
11. Henry C, "Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia", Proc(Bayl Univ Med Cent), 31, pp.419~423 (2018)
12. Myles PR, "The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort", Pharmacoepidemiol Drug Saf, 18, pp.697~703 (2009)
13. Wan Beom Park, "Virus Isolation from the First Patient with SARS-CoV-2 in Korea", Journal of Korean Medical Science, 35(7), pp.1~5 (2020), 대한의학회[DOI]
14. Corman VM, "Detection of 2019novel coronavirus(2019-nCoV)by real-time RT-PCR", Euro Surveill, 25, pp.2000045~ (2020)
15. Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
16. Wu A, "The association of cardio protective medications with pneumonia-related outcomes", PLoS One, 9, pp.e85797~ (2014)
17. Mehra MR, "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis", Lancet (2020)
18. Mancia G, "Renin-angiotensin-aldosterone system blockers and the risk of COVID-19", N Engl J Med, 382, pp.2431~2440 (2020)
19. Mehra MR, "Cardiovascular disease, drug therapy, and mortality in COVID-19", N Engl J Med, 382, pp.e102~ (2020)
20. Zhang P, "Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19", Circ Res, 126, pp.1671~1681 (2020)
21. Li J, "Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019(COVID-19)infection in Wuhan, China", JAMA Cardiol, 5, pp.825~830 (2020)
22. Meng J, "Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19patients with hypertension", Emerg Microbes Infect, 9, pp.757~760 (2020)
23. de Abajo FJ, "Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital : a casepopulation study", Lancet, 395, pp.1705~1714 (2020)
24. Reynolds HR, "Reninangiotensin-aldosterone system inhibitors and risk of covid-19", N Engl J Med, 382, pp.2441~2448 (2020)
25. Khera R, "Association of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19", medRxiv 2020 May 19. https:, doi.org, pp.10.1101, 2020.05.17.20104943[DOI]
26. Bean DM, "Angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust", Eur J Heart Fail, 22, pp.967~974 (2020)
27. Feng Y, "COVID-19 with different severities : a multicenter study of clinical features", Am J Respir Crit Care Med, 201, pp.1380~1388 (2020)
28. Rentsch CT, "Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans : a nationwide cohort study", PLoS Med, 17, pp.e1003379~ (2020)
29. Peng YD, "Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV", Zhonghua Xin Xue Guan Bing Za Zhi, 48, pp.450~455 (2020)
30. Zeng Z, "Hypertension in patients hospitalized with COVID-19 in Wuhan, China: a singlecenter retrospective observational study", medRxiv 2020 Apr 11. https:, doi.org, pp.10.1101, 2020.04.06.20054825[DOI]
31. Yang G, "Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension", medRxiv 2020 Apr 4. https:, doi.org, pp.10.1101, 2020.03.31.20038935[DOI]
32. Giorgi Rossi P, "Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy", PLoS One, 15, pp.e0238281~ (2020)
33. Yan F, "Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients", Cell Discov, 6, pp.77~ (2020)
34. "Rex: Excel-based statistical analysis software" (2018)[URL]
35. Won S, "Choosing an optimal method to combine P-values", Stat Med, 28, pp.1537~1553 (2009)
36. Korean Society Hypertension (KSH), "Korea hypertension fact sheet 2018", Clin Hypertens, 24, pp.13~ (2018)
37. Caldeira D, "Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers:systematic review and meta-analysis", BMJ, 345, pp.e4260~ (2012)
38. Hsu WT, "Effect of reninangiotensin-aldosterone system inhibitors on short-term mortality after sepsis : a population-based cohort study", Hypertension, 75, pp.483~491 (2020)
39. Wenz M, "Inhaled nitric oxide does not change transpulmonary angiotensin II formation in patients with acute respiratory distress syndrome", Chest, 112, pp.478~483 (1997)
40. Jerng JS, "Role of the reninangiotensin system in ventilator-induced lung injury : an in vivo study in a rat model", Thorax, 62, pp.527~535 (2007)
41. Wosten-van Asperen RM, "ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin", Eur Respir J, 31, pp.363~371 (2008)
42. Wang R, "Angiotensin II induces apoptosis in human and rat alveolar epithelial cells", Am J Physiol, 276, pp.L885~L889 (1999)
43. Jung KH, "Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage", J Pharmacol Exp Ther, 322, pp.1051~1058 (2007)
44. Wiel E, "Effects of the angiotensinconverting enzyme inhibitor perindopril on endothelial injury and hemostasis in rabbit endotoxic shock", Intensive Care Med, 30, pp.1652~1659 (2004)
45. Chen C, "Losartan attenuates microvascular permeability in mechanical ventilator-induced lung injury in diabetic mice", Mol Biol Rep, 41, pp.809~814 (2014)
46. Asmussen S, "The angiotensinconverting enzyme inhibitor captopril inhibits poly(adpribose)polymerase activation and exerts beneficial effects in an ovine model of burn and smoke injury", Shock, 36, pp.402~409 (2011)
47. Gullestad L, "Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure", J Am Coll Cardiol, 34, pp.2061~2067 (1999)
48. Shao J, "Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury", Hypertension, 42, pp.31~38 (2003)
49. Yang P, "Angiotensin-converting enzyme 2(ACE2)mediates influenza H7N9 virus-induced acute lung injury", Sci Rep, 4, pp.7027~ (2014)
50. ONTARGET Investigators, "Telmisartan, ramipril, or both in patients at high risk for vascular events", N Engl J Med, 358, pp.1547~1559 (2008)
51. Lv X, "Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis", Medicine (Baltimore), 97, pp.e0256~ (2018)
52. Brugts JJ, "Impact of reninangiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension : a numberneeded-to-treat analysis", Int J Cardiol, 181, pp.425~429 (2015)
53. Ceconi C, "ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study : PERTINENT", Cardiovasc Res, 73, pp.237~246 (2007)
54. 박성하, "Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?", Clinical Hypertension, 26(3), pp.26~30 (2020), 대한고혈압학회[DOI]
55. Kwan-Yong Lee, "Consensus Statement on Coronary Intervention during the Coronavirus Disease 2019 (COVID-19) Pandemic: from the Korean Society of Interventional Cardiology (KSIC)", Korean Circulation Journal, 50(11), pp.974~983 (2020), 대한심장학회[DOI]
56. Kwan Yong Lee, "Consensus statement on coronary intervention during the coronavirus disease 19 pandemic: from the Korean Society of Interventional Cardiology", The Korean Journal of Internal Medicine, 35(4), pp.749~757 (2020), 대한내과학회[DOI]
57. Shrank WH, "Healthy user and related biases in observational studies of preventive interventions : a primer for physicians", J Gen Intern Med, 26, pp.546~550 (2011)

관련 논문AI추천